RxDoctor Payments Data

George Bordenave, MD

Cardiovascular Disease · Miami, FLNPI 1326035767

Payments from drug & device makers

$1,550in general payments, 2019–2025

Across 69 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$262
  • E.r. Squibb & Sons, L.L.C.$216
  • Esperion Therapeutics, Inc.$206
  • Novartis$139
  • Boston Scientific$128
  • Impulse Dynamics (USA) Inc.$117
  • plus $483 from 10 others

What the payments were for

  • Food & beverage$1,550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,550 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$98,473
Medicare patients
334
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$119,442
FarxigaDapagliflozin Propanediol94$74,190
EntrestoSacubitril/Valsartan35$48,961
XareltoRivaroxaban29$30,369
JardianceEmpagliflozin26$22,240
Metoprolol Succinate276$1,977
Doxazosin Mesylate127$1,311
Nifedipine ErNifedipine40$782
Losartan Potassium131$686
Atorvastatin Calcium62$343
Lisinopril71$310
Citalopram HbrCitalopram Hydrobromide84$259
Enalapril Maleate24$189
Labetalol Hcl11$122
Carvedilol16$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$119,442121 claims
AstraZenecaFarxiga$262$74,19094 claims
NovartisEntresto$139$48,96135 claims
Johnson & JohnsonXarelto$94$30,36929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →